Reynders McVeigh Capital Management LLC Has $3.85 Million Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Reynders McVeigh Capital Management LLC decreased its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 18.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 97,687 shares of the company's stock after selling 21,899 shares during the quarter. Reynders McVeigh Capital Management LLC owned 0.11% of CRISPR Therapeutics worth $3,845,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of CRSP. The Manufacturers Life Insurance Company increased its stake in CRISPR Therapeutics by 1.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company's stock valued at $586,000 after buying an additional 231 shares during the period. Intellectus Partners LLC increased its stake in shares of CRISPR Therapeutics by 3.6% in the fourth quarter. Intellectus Partners LLC now owns 7,131 shares of the company's stock worth $281,000 after acquiring an additional 250 shares during the last quarter. Farrow Financial Inc. raised its holdings in shares of CRISPR Therapeutics by 1.4% during the fourth quarter. Farrow Financial Inc. now owns 20,097 shares of the company's stock worth $777,000 after acquiring an additional 270 shares in the last quarter. Sunbelt Securities Inc. boosted its position in CRISPR Therapeutics by 11.3% during the third quarter. Sunbelt Securities Inc. now owns 2,955 shares of the company's stock valued at $139,000 after purchasing an additional 300 shares during the last quarter. Finally, Kestra Private Wealth Services LLC grew its stake in CRISPR Therapeutics by 1.5% in the fourth quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company's stock valued at $812,000 after purchasing an additional 310 shares in the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the transaction, the general counsel now directly owns 77,530 shares in the company, valued at approximately $3,288,822.60. The trade was a 3.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,381 shares of company stock worth $1,608,243 over the last quarter. 4.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on CRSP shares. Morgan Stanley increased their target price on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an "underweight" rating in a research report on Friday, February 14th. HC Wainwright reaffirmed a "buy" rating and set a $65.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. JMP Securities restated a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. TD Cowen raised shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price target for the company in a research note on Wednesday, February 12th. Finally, Bank of America lowered their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $73.11.

CRISPR Therapeutics Trading Down 0.0 %

Shares of NASDAQ CRSP traded down $0.01 during mid-day trading on Thursday, hitting $37.77. The company had a trading volume of 1,027,190 shares, compared to its average volume of 1,631,359. CRISPR Therapeutics AG has a one year low of $30.04 and a one year high of $67.88. The company has a market capitalization of $3.24 billion, a PE ratio of -8.64 and a beta of 1.85. The firm has a 50-day simple moving average of $41.00 and a two-hundred day simple moving average of $43.87.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Sell-side analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.